Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹6.82
-₹0.12(-1.73%)
At close: 4:00 PM EDT
₹6.82
-₹0.12(-1.73%)
Day’s Range― - ―
52-Week Range₹5.13 - ₹12.46
Previous CloseN/A
Volume22.89K
Average Volume (3M)1.72K
Market Cap
₹265.04M
Enterprise Value₹375.08M
Total Cash (Recent Filing)₹6.97M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)-3.30
Shares Outstanding50,101,240
10 Day Avg. Volume1,876
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
API And Intermediate ManufacturingSupplying APIs and intermediates places LASA within the pharmaceutical production chain, where its products are essential inputs for finished medicines. This business model can support recurring demand across multiple formulation programs if the company restores operational performance and maintains regulatory readiness.
Therapeutic And Geographic ReachServing domestic and export customers across multiple therapeutic categories provides a broader commercial base than dependence on one medicine or market. This diversification can help spread product-specific demand swings and preserve growth opportunities when individual molecules or regions weaken.
Manageable LeverageRelatively low leverage gives LASA some balance-sheet flexibility despite its operating losses. With debt-to-equity around 0.20, the company faces less fixed financial pressure than a highly indebted business, preserving some capacity to manage obligations while attempting an operational recovery.
Bears Say
Severe Revenue ContractionThe sharp FY2026 revenue decline, following a broader downward trend from FY2021, indicates substantial deterioration in demand, volumes, pricing, or operating execution. Persistent top-line contraction reduces scale benefits and makes a durable recovery in profitability more difficult.
Deeply Negative ProfitabilityNegative gross and net margins show that current operations are not covering the cost base, while losses have continued across several fiscal years. Persistent unprofitability can erode equity, restrict reinvestment, and leave future earnings dependent on a meaningful improvement in pricing or efficiency.
Weak Cash GenerationRepeatedly negative operating cash flow means the business is not currently converting operations into internally generated funding. This weakens financial resilience, limits self-funded investment, and increases reliance on existing balance-sheet resources unless cash generation improves materially.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.13 and its highest was ₹12.46 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹265.04M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.714 earnings per share for the quarter.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of 0.67%. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.714 in its last earnings report. Following the earnings report the stock price went up 1.743%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―